Suppr超能文献

[肺鳞状细胞癌驱动癌基因的研究进展]

[Advances on driver oncogenes of squamous cell lung cancer].

作者信息

Hong Wei, Zhang Yiping

机构信息

Zhejiang Cancer Hospital, Zhejiang Key Laboratory of the Diagnosis & Treatment Technology on Thoracic Oncology, 
Hangzhou 310022, China.

出版信息

Zhongguo Fei Ai Za Zhi. 2014 May;17(5):433-6. doi: 10.3779/j.issn.1009-3419.2014.05.13.

DOI:10.3779/j.issn.1009-3419.2014.05.13
PMID:24854563
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6000441/
Abstract

Lung cancer is the leading cause of cancer-related deaths worldwide. Next to adenocarcinoma, squamous cell carcinoma (SCC) of the lung is the most frequent histologic subtype in non-small cell lung cancer. Several molecular alterations have been defined as "driver oncogenes" responsible for both the initiation and maintenance of the malignancy. The squamous cell carcinoma of the lung has recently shown peculiar molecular characteristics which relate with both carcinogenesis and response to targeted drugs. So far, about 40% of lung squamous cell carcinoma has been found harbouring driver oncogenes, in which fibroblast growth factor receptor 1 (FGFR1) plays important roles. In this review, we will report the mainly advances on some latest driver mutations of squamous cell lung cancer.

摘要

肺癌是全球癌症相关死亡的主要原因。在非小细胞肺癌中，肺鳞状细胞癌（SCC）是仅次于腺癌的最常见组织学亚型。几种分子改变已被定义为负责恶性肿瘤起始和维持的“驱动癌基因”。肺鳞状细胞癌最近显示出与致癌作用和靶向药物反应相关的独特分子特征。到目前为止，已发现约40%的肺鳞状细胞癌携带驱动癌基因，其中成纤维细胞生长因子受体1（FGFR1）发挥重要作用。在本综述中，我们将报告肺鳞状细胞癌一些最新驱动突变的主要进展。

相似文献

1
[Advances on driver oncogenes of squamous cell lung cancer].
Zhongguo Fei Ai Za Zhi. 2014 May;17(5):433-6. doi: 10.3779/j.issn.1009-3419.2014.05.13.
2
[Advances on driver oncogenes of lung adenocarcinoma].
Zhongguo Fei Ai Za Zhi. 2013 Feb;16(2):91-6. doi: 10.3779/j.issn.1009-3419.2013.02.06.
3
[Advances on driver oncogenes of non-small cell lung cancer].
Zhongguo Fei Ai Za Zhi. 2015 Jan;18(1):42-7. doi: 10.3779/j.issn.1009-3419.2015.01.07.
4
FGFR1 gene amplification in squamous cell carcinomas of the lung: a potential favorable prognostic marker for women and for patients with advanced cancer.
Virchows Arch. 2018 May;472(5):759-769. doi: 10.1007/s00428-017-2282-0. Epub 2017 Dec 21.
5
Expression of fibroblast growth factor receptor 1, fibroblast growth factor 2, phosphatidyl inositol 3 phosphate kinase and their clinical and prognostic significance in early and advanced stage of squamous cell carcinoma of the lung.
Int J Clin Exp Pathol. 2015 Sep 1;8(9):9760-71. eCollection 2015.
6
FGFR1/3 tyrosine kinase fusions define a unique molecular subtype of non-small cell lung cancer.
Clin Cancer Res. 2014 Aug 1;20(15):4107-14. doi: 10.1158/1078-0432.CCR-14-0284. Epub 2014 May 21.
7
FGFR1 amplification in squamous cell carcinoma of the lung.
J Thorac Oncol. 2012 Dec;7(12):1775-1780. doi: 10.1097/JTO.0b013e31826aed28.
8
Mutational Landscape of DDR2 Gene in Lung Squamous Cell Carcinoma Using Next-generation Sequencing.
Clin Lung Cancer. 2018 Mar;19(2):163-169.e4. doi: 10.1016/j.cllc.2017.10.006. Epub 2017 Oct 19.
9
Increased FGFR1 copy number in lung squamous cell carcinomas.
Mol Med Rep. 2012 Mar;5(3):725-8. doi: 10.3892/mmr.2011.715. Epub 2011 Dec 15.
10
Fibroblast growth factor receptor 1 gene amplification and protein expression in human lung cancer.
Cancer Med. 2020 May;9(10):3574-3583. doi: 10.1002/cam4.2994. Epub 2020 Mar 24.

引用本文的文献

1
Elucidating the clonal relationship of esophageal second primary tumors in patients with laryngeal squamous cell carcinoma.
Infect Agent Cancer. 2023 Nov 28;18(1):75. doi: 10.1186/s13027-023-00558-z.

本文引用的文献

1
Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial.
Lancet Oncol. 2013 Sep;14(10):953-61. doi: 10.1016/S1470-2045(13)70355-3. Epub 2013 Aug 13.
2
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.
N Engl J Med. 2013 Jun 20;368(25):2385-94. doi: 10.1056/NEJMoa1214886. Epub 2013 Jun 1.
3
Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET.
Clin Cancer Res. 2013 May 1;19(9):2381-92. doi: 10.1158/1078-0432.CCR-12-3459. Epub 2013 Mar 26.
4
Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer.
J Clin Oncol. 2013 Feb 20;31(6):731-7. doi: 10.1200/JCO.2012.43.8622. Epub 2012 Nov 26.
5
FGFR1 amplification in squamous cell carcinoma of the lung.
J Thorac Oncol. 2012 Dec;7(12):1775-1780. doi: 10.1097/JTO.0b013e31826aed28.
6
Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Positive Non-Small-Cell Lung Cancer.
Clin Lung Cancer. 2012 Nov;13(6):500-4. doi: 10.1016/j.cllc.2012.05.009.
7
Comprehensive genomic characterization of squamous cell lung cancers.
Nature. 2012 Sep 27;489(7417):519-25. doi: 10.1038/nature11404. Epub 2012 Sep 9.
8
Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01): an open-label, phase 3 trial.
Cancer. 2012 Dec 15;118(24):6234-42. doi: 10.1002/cncr.27630. Epub 2012 Jun 6.
9
Squamous cell carcinoma of the lung: molecular subtypes and therapeutic opportunities.
Clin Cancer Res. 2012 May 1;18(9):2443-51. doi: 10.1158/1078-0432.CCR-11-2370. Epub 2012 Mar 8.
10
Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.
Cancer Discov. 2011 Jun;1(1):78-89. doi: 10.1158/2159-8274.CD-11-0005.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验